Most Read Articles
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.
15 Sep 2019
Podcast: Dr Shamir Mehta briefly discusses the clinical impact of findings from the COMPLETE trial
16 Sep 2019
Podcast: Prof Derek Chew explains the importance of a 1-hour troponin T protocol in suspected ACS as discussed in the RAPID-TnT trial
15 Sep 2019
Sodium-glucose transport protein 2 (SGLT2) inhibitors exert a putative epigenetic regulation of the protecting cardiovascular effect, reports a study, adding that dapagliflozin may protect the kidneys by preserving renal vasodilating capacity.

Tofogliflozin safe, effective for seniors with T2DM

22 Aug 2019

Tofogliflozin is safe and effective for elderly patients with type 2 diabetes mellitus (T2DM), regardless of insulin and oral antidiabetic drugs (OADs), reports a new Japan study.

Conducting a subanalysis of the J-STEP/EL* study, researchers evaluated the safety and efficacy of tofogliflozin in 1,497 elderly T2DM patients (mean age, 72.4±6.0 years; 52.4 percent female) who started the medication within the first 3 months of its launch.

A total of 271 patients reported adverse drug reactions (ADR), resulting in an incidence rate of 18.10 percent. There were 33 patients (2.20 percent) who experienced serious ADRs. Volume depletion-related ADRs were the most common (3.94 percent), followed by polyuria/pollakiuria (2.94 percent) and skin disorders (2.40 percent). The incidence rate of hypoglycaemia was 1.07 percent.

In terms of efficacy, researchers observed a significant drop in glycated haemoglobin (HbA1c) over time. From a baseline value of 7.64±1.35 percent, HbA1c decreased to 7.17±1.16 percent at the last observation. The mean change of –0.46±1.02 percent was statistically significant (p<0.001).

Efficacy of tofogliflozin did not meaningfully change according to the number of OADs. In those taking zero, one, two and ≥3 OADs, the mean change in HbA1c values from baseline were –0.34±0.91 percent, –0.42±1.06 percent, –0.56±1.03 percent and –0.50±1.07 percent, respectively (p<0.001 for all).

Similarly, insulin did not interfere with the effect of tofogliflozin, such that those taking the hormone showed a significant mean HbA1c change of –0.44±0.89 percent (p<0.001).

*Japanese Study of Tofogliflozin with Type 2 Diabetes Mellitus Patients in an Observational Study of the Elderly

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.
15 Sep 2019
Podcast: Dr Shamir Mehta briefly discusses the clinical impact of findings from the COMPLETE trial
16 Sep 2019
Podcast: Prof Derek Chew explains the importance of a 1-hour troponin T protocol in suspected ACS as discussed in the RAPID-TnT trial
15 Sep 2019
Sodium-glucose transport protein 2 (SGLT2) inhibitors exert a putative epigenetic regulation of the protecting cardiovascular effect, reports a study, adding that dapagliflozin may protect the kidneys by preserving renal vasodilating capacity.